Visioneering Wins Award of Excellence for Its NaturalVue® Multifocal 1 Day Contact Lenses at Australia’s Largest Eyecare...
23 July 2019 - 10:00AM
Business Wire
US-based medical device company Visioneering Technologies
Inc. (ASX: VTI) (‘Visioneering’ or ‘The Company’) is pleased to
announce that it has received the Award of Excellence for its
innovative NaturalVue® (etafilcon A) Multifocal 1 Day Contact
Lenses at the O=MEGA 19 event in Melbourne, Australia. O=MEGA 19 is
the largest eyecare and eyewear event in Australia, replacing and
combining the Southern Regional Congress (SRC) and Optical
Distributors & Manufacturers Association of Australia (ODMA)
Fair.
NaturalVue Multifocal (NVMF) was selected as the best in
innovation and technology among some of the industry’s strongest
competitors including Alcon’s Dailies Total 1 Contact Lenses and
Bausch & Lomb’s Ultra for Astigmatism. The awards were judged
by an expert independent panel consisting of Professor Fiona
Stapleton, PhD, UNSW; Steven Daras, Teacher, Optical Dispenser
& Course Coordinator TAFE Digital; Richard Banks, Independent
Optometrist; and Lyndal Frollano, former Creative Director of
Harper’s Bazaar Magazine.
NVMF contact lenses feature Visioneering’s innovative Neurofocus
Optics® Technology which employs a patented extended depth-of-focus
design. The innovative NVMF lens design allows it to be used for
both myopic progression control and presbyopia (the age-related
loss of ability to see near objects).
Visioneering’s Senior Vice President, Sales and Marketing, Tony
Sommer commented, “We are extremely proud to win the Award of
Excellence for Contact Lenses at O=MEGA 19. NaturalVue Multifocal
is a significant addition to the myopia toolkit for optometrists,
and we thank the judges for recognizing our technological
edge.”
Dr. Peg Achenbach, FAAO, Vice President of Professional Services
and Clinical Science, was on hand to accept the award on behalf of
Visioneering. Dr. Achenbach was at O=MEGA19 to deliver a talk on
the topic of: ‘Extended Depth of Focus Contact Lenses – A Novel
Approach to Myopia Control’.
O=MEGA19 was established by the ODMA and Optometry
Victoria/South Australia. The three-day event brings together
leading participants from the global optical industry and comprises
a clinical conference, a trade fair and masterclasses.
NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens
Indication for Use in Europe and Australia and New Zealand:
NaturalVue (etafilcon A) Multifocal Daily Disposable Soft
(Hydrophilic) Contact Lenses are indicated for daily wear for the
correction of refractive ametropia (myopia and hyperopia) and/or
presbyopia, and myopia progression control in aphakic and/or
non-aphakic persons with non-diseased eyes in powers from -20.00 to
+20.00 dioptres and with non-diseased eyes who may require a
reading addition of up to +3.00D. The lenses may be worn by persons
who exhibit astigmatism of 2.00 dioptres or less that does not
interfere with visual acuity.
About Visioneering Technologies Inc.
Visioneering Technologies Inc. (ASX: VTI) is an innovative eye
care company committed to redefining vision. Since its founding in
2008, Visioneering has brought together clinical, marketing,
engineering, manufacturing and regulatory leaders from top vision
care businesses to provide new solutions for presbyopia, myopia and
astigmatism.
Headquartered in the US, Visioneering designs, manufactures,
sells and distributes contact lenses. Its flagship product is the
NaturalVue® Multifocal contact lens, and VTI has expanded its
portfolio of technologies to address a range of eye care issues.
The company has grown operations across the United States,
Australia and Europe and is expanding into Asia with a focus on
markets with high rates of myopia.
MKT-ANZ-PR4 r0
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190722005735/en/
Layna L. Mendlinger info@vtivision.com
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Dec 2023 to Dec 2024